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AbstrACt
Objectives To investigate public perceptions of 
overdiagnosis and overtreatment in low-risk thyroid cancer 
and explore opinions regarding the proposed strategy to 
change the terminology of low-risk cancers.
Design Qualitative study using focus groups that included 
a guided group discussion and presentation explaining 
thyroid cancer, overdiagnosis and overtreatment, and 
proposed communication strategies. Transcripts were 
analysed thematically.
setting Sydney, Australia.
Participants Forty-seven men and women of various 
ages from a range of socioeconomic backgrounds with no 
personal history of thyroid cancer.
results Participants had low pre-existing general 
awareness of concepts of overdiagnosis and overtreatment 
and expressed concern regarding this new information in 
relation to thyroid cancer. Overall, participants understood 
why the strategy to change the terminology was being 
proposed and could see potential benefits including 
reducing the negative psychological impact and stigma 
associated with the term ‘cancer’; however, many still 
had reservations about the strategy. The majority of the 
concerns were around their worry about the risk of further 
disease progression and that changing the terminology 
may create confusion and cause patients not to take the 
diagnosis and its associated managements seriously. 
Despite varied views towards the proposed strategy, there 
was a strong overarching desire for greater patient and 
public education around overdiagnosis and overtreatment 
in both thyroid cancer and cancer generally in order 
to complement any revised terminology and/or other 
mitigation strategies.
Conclusions We found a strong and apparently widely 
held desire for more information surrounding the topic of 
overdiagnosis and overtreatment. Careful consideration of 
how to inform both the public and current patients about 
the implications of a change in terminology, including 
changes to patients’ follow-up or treatments, would be 
needed if such a change were to go ahead.
IntrODuCtIOn
In recent years, the incidence of thyroid 
cancer has dramatically increased worldwide, 
driven largely by the detection of papillary 
thyroid cancers (PTCs)1 which are typically 
small and slow-growing. Autopsy studies 
conducted on people who died of causes 
unrelated to the thyroid revealed latent PTCs 
in more than 10% of the general population.2 
The existence of this reservoir of indolent 
disease, increasing use of clinical imaging 
and more intensive pathological scrutiny 
of thyroid resection specimens has led to 
increased incidental detection and diagnosis 
of small PTCs.3 Although rates vary, approx-
imately half of new cases of PTC have been 
reported to be <1 cm in diameter (known as 
papillary thyroid microcarcinomas)4–6 
Most patients with PTC are treated with 
thyroid surgery (either total thyroidectomy 
or hemithyroidectomy). However, Japanese 
studies have shown that in patients with 
subcentimetre  PTCs (low-risk PTCs), active 
surveillance leads to similar disease outcomes 
(growth, metastasis and mortality) compared 
with those who undergo immediate surgery.7 
The potential for primary active surveillance 
of low-risk PTCs is significant as thyroid 
surgery may cause complications, including 
the risk of voice changes and issues with main-
tain normal calcium levels.8 Furthermore, 
lifelong reliance on daily thyroid hormone 
replacement medication is required for 
strengths and limitations of this study
 ► First study to investigate public perceptions of in-
formation about thyroid cancer overdiagnosis and 
overtreatment and responses to the possibility of 
changing the terminology of low-risk cancers.
 ► Participants varied in age, gender and socioeco-
nomic status and were recruited using random digit 
dialling by an independent professional recruitment 
company.
 ► Information provided to participants was developed 
by a multidisciplinary team, including a consumer 
representative, and was reviewed by two indepen-
dent thyroid cancer clinicians.
 ► Due to the amount and complexity of information, 
participants may not have comprehensively under-
stood all concepts presented.
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all thyroidectomy patients and a small proportion of 
hemithyroidectomy patients with its own burden of treat-
ment.9 Although its use has been shown to be limited in 
clinical practice,10 the option of active surveillance for 
low-risk PTCs is beginning to be acknowledged in clinical 
practice guidelines.11
This rise of thyroid cancer incidence and the preferred 
used of thyroid surgery as a treatment option for low-risk 
PTC has raised concerns about thyroid cancer overdiag-
nosis and overtreatment.12 Recently, changing the termi-
nology used to describe low-risk conditions has been 
recommended as a possible solution, to help prevent 
overdiagnosis and the associated harms of overtreat-
ment.3 13 14 Studies have previously shown how different 
terminologies affect treatment preferences for non-inva-
sive breast cancer (ductal carcinoma in situ; DCIS),15 16 and 
more recently similar studies have demonstrated similar 
findings for low-risk PTC.17 Removing the term ‘cancer’ 
in the description of both of these conditions led to 
higher preferences for non-surgical treatment in research 
settings. A recent systematic review, which includes the 
studies on DCIS, supports these findings and shows that 
the terminology used to describe various conditions can 
impact people’s decisions about treatment as well as 
their psychological responses.18 Additionally, reference 
to ‘cancer’ was recently removed from a subtype of PTC 
(‘non-invasive follicular thyroid neoplasm with papil-
lary-like nuclear features’), which is identified after a total 
or hemithyroidectomy, to eliminate the need for ongoing 
follow-up and reduce potential patient anxiety.19 Taken 
together, this evidence indicates that removing ‘cancer’ 
from the terms used to describe of low-risk conditions, 
including low-risk PTC, may ameliorate adverse psycho-
logical outcomes, reduce overtreatment and is achievable 
in real world practice. However, to our knowledge there 
has as yet been no investigation of community percep-
tions of this strategy.
In this study, we aimed to investigate community percep-
tions of overdiagnosis and overtreatment in PTC, and the 
proposal to change the terminology of low-risk PTC to 
help inform mitigation strategies for overdiagnosis and 
overtreatment in this and other low-risk cancers.
MethODs
study design
We conducted a qualitative focus group study to investi-
gate what the community thought and felt about thyroid 
cancer overdiagnosis and overtreatment communica-
tion. The qualitative design involving focus groups with 
face-to-face contact with participants helped enable us to 
communicate potentially counterintuitive information 
about thyroid cancer and overdiagnosis20 effectively.
Participant recruitment
We recruited a community sample of men and women in 
Sydney, Australia aged ≥18 years with no previous diag-
nosis of thyroid cancer to ensure that participants would 
not be biased by previous experience of diagnosis and 
treatment. An independent research recruitment organ-
isation (Taverner Research) used random digit dialling 
to approach potential participants. Trained Taverner 
interviewers used a brief series of questions to deter-
mine participant eligibility, with participants not fluent 
in English and those with a personal diagnosis of thyroid 
cancer excluded. To gain a diverse range of perspectives, 
we used quota sampling to ensure inclusion of partici-
pants with varying levels of education. Those who agreed 
to participate were emailed a participant information 
statement and consent form. Each participant was given 
a $100 gift voucher as a thank you for their attendance.
We aimed to conduct six focus groups with approx-
imately eight participants in each in order to achieve 
thematic saturation as indicated by data redun-
dancy,21 22 that is, when participants no longer raised orig-
inal themes.
Patient and public involvement
A consumer representative (from Health Care Consumers’ 
Association) was involved in the development and review 
of study materials. Study participants were a community 
sample recruited from the general Australian public.
Focus group presentation and discussion
The focus groups were conducted in February 2018. 
Sessions were convened at three locations that were 
convenient to the participants. Each session comprised: 
introduction and consent, demographic questionnaire, 
warm-up discussion, a detailed presentation and a 
final questionnaire. The presentation was divided into 
sections and interspersed with guided discussions about 
the content. Sessions lasted approximately 2 hours and 
were facilitated by two female moderators (BN and CS). 
Both moderators had experience and/or were trained in 
conducting qualitative focus groups and interviews.
At each focus group, BN gave an audiovisual presen-
tation (see online supplementary appendix 1 for slides) 
that had been developed and reviewed by a multidisci-
plinary team of public health researchers with an interest 
in reducing overdiagnosis and overtreatment, health 
psychologists, clinicians, thyroid cancer experts and 
a consumer representative. Two independent thyroid 
cancer clinicians also reviewed the presentation before 
the focus groups commenced. The presentation included 
a combination of pictures, plain language and info-
graphics appropriate for a range of numeracy levels.23 We 
presented a range of published evidence showing overdi-
agnosis3 24 and overtreatment7 of thyroid cancer using 
simple pictograms, and annotated graphs. The presenta-
tion was piloted with three different groups resulting in 
minor refinement.
In the group discussions, participants shared their 
responses to the information presented and how they felt 
about overdiagnosis and overtreatment in thyroid cancer 
and the proposed strategy of changing low-risk cancer 
terminology. Box 1 summarises the presentation content 
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and gives an example of the types of questions asked to 
guide the discussions. At the beginning of each group we 
made it clear that some information presented may be unfa-
miliar, or cause disagreements among the group. We high-
lighted that we wanted to hear their honest thoughts and 
opinions and emphasised our neutrality to participant’s 
opinions throughout by repeating statements of this kind, 
and by not interpreting views expressed by participants as 
positive or negative. A proposed strategy for thyroid cancer 
communication was able to be debated for and against, and 
these contrasting opinions led participants to articulate 
their own points of view in greater depth.25 Throughout 
the presentation, we strongly encouraged participants to 
request clarification as often as required.
Data collection and analysis
Focus group discussions were audio recorded, transcribed 
verbatim and analysed to identify recurring themes 
and data patterns. The data was managed using NVivo 
V.11 software. The analysis initially took a data-driven 
approach to ensure that the findings were grounded in 
participant’s responses. Two researchers (BN and CS) 
independently reviewed transcripts in NVivo and devel-
oped codes in an iterative process. This approach, along 
with the research questions that shaped the presentation 
and the notes taken by researchers (BN and CS) during 
and following each focus group, formed the basis of the 
initial coding framework. Using constant comparison,21 26 
the two researchers continually looked for similarities and 
differences in the data and in coding within and across 
transcripts. By comparing and discussing each aspect 
of the data a final coding framework developed. Final 
coding was performed by the two researchers in NVivo, 
with BN coding all of the data and CS double coding half. 
Once coded, the data was examined to identify overar-
ching themes and concepts. Throughout this process, the 
two researchers met regularly with qualitative expert KM, 
and the coding framework and data interpretation were 
discussed and agreed on with members of the research 
team.
We also administered brief written questionnaires at the 
start and end of each focus group, which included ques-
tions about demographics (multiple choice responses), 
reactions and opinions regarding overdiagnosis (5-point 
Likert scale and yes/no responses), overtreatment and 
terminology changes (yes/no and free-text responses) 
and preferred alternate terminologies for low-risk PTCs 
(multiple choice and free-text responses). BN and CS 
collated and read through all of the questionnaire 
responses. Demographic responses, health literacy,27 
cancer worry28 and participant’s anxiety scores29 30 have 
been included in table 1, and the other responses were 
discussed and pooled with transcript data when analysing 
key overarching concepts.
results
Participant characteristics
Twenty-one men and twenty-six women of various ages 
from a range of socioeconomic backgrounds took part in 
six focus groups (table 1). Nineteen participants (40%) 
had a university degree or above which is slightly higher 
than that of the general Australian population.31 Three 
participants (6%) had experienced a personal diagnosis 
of cancer other than thyroid cancer and 29 (62%) had 
an immediate family member with a diagnosis of cancer. 
Overall, the sample reported low levels of cancer worry 
and general anxiety.
The thematic analysis identified three main themes 
arising from the focus groups’ discussions: (1) partici-
pants’ initial perceptions and understanding of thyroid 
cancer, (2) reactions to thyroid cancer overdiagnosis 
and overtreatment information and (3) views and opin-
ions about the strategy of changing the terminology. 
The latter two themes are further broken down into a 
number of subthemes which formed the majority of the 
box 1 Focus group presentation topics and key 
discussion questions
 ► Introduction to thyroid cancer (nature, detection and treatment).
 ► Introduction to cancer overdiagnosis, with graph to illustrate the 
varying growth rates of cancers and efficacy of screening.
 ► Introduction to overtreatment.
 ► Evidence of thyroid cancer overdiagnosis and overtreatment, vari-
ous studies explained with statistical visuals:
 – Autopsy studies showing latent thyroid cancers in 10% of the 
general population,2 with shaded pictogram.
 – Dramatic increase in South Korean thyroid cancer incidence with 
little change in mortality rate,24 with annotated graph.
 – Japanese studies showing similar outcomes in disease progres-
sion and death between patients who chose to monitor their 
small papillary thyroid cancers with scans and those who chose 
immediate surgery.7
 – How do you feel about overdiagnosis and overtreatment of thy-
roid cancer?
 ► Introduction to proposed strategy of changing the terminology used 
to describe low-risk cancers, with graphic showing increased power 
of technology to detect cancer and excerpts of recommendations 
from reputable journals:
 – Overall, how do you feel about this proposed strategy—to 
change the terminology of low-risk cancers including papillary 
thyroid cancer?
 – What do you think are the pros and cons of this strategy? With 
responses tabulated on a whiteboard.
 ► Evidence of changing terminology, with examples of changed 
terminologies:
 – If some sort of change to the terminology of low-risk thyroid can-
cers were to be made, what do you think would be the best term 
to use?
 – Some terms have already been proposed or tested. These are 
‘abnormal cells’, ‘lesion’ and ‘neoplasm/neoplasia’. How do you 
feel about these terms?
 ► Other possible descriptions, with the following words arranged on 
screen: ‘cyst’, ‘lump’, ‘indolent lesion’, ‘precancer’, ‘benign’, ‘nod-
ule’, ‘pre-invasive’, ‘common growth’, ‘standard tumour’, ‘prelimi-
nary mass’, ‘others’:
 – Which terms do you think best explain these types of conditions?
 – Do you have any ideas about other possible terms?
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discussion and data collected. Participants’ quotations 
have been selected to demonstrate both common and 
diverse responses.
Participants initial perceptions and understanding of thyroid 
cancer
Across the focus groups most people had little knowledge 
of thyroid cancer which was evident in the number of 
general questions about thyroid cancer asked by partic-
ipants in each group. While most had heard of thyroid 
cancer, the majority of participants did not know how it is 
detected, diagnosed and treated. Participants perceived 
thyroid cancer to be quite similar to other types of cancer 
in terms of the risk of the morbidity and mortality. Overall, 
participants believed that all cancers were harmful and 
deadly.
…with cancer we’re constantly told like… it’s going 
to get us, everyone… (FG3)
See like I think of cancer as like… you’re very sick, 
like almost certain to be terminally ill. (FG4)
reactions to thyroid cancer overdiagnosis and overtreatment 
information
Uncertainty about overdiagnosis and overtreatment
There was initially some overall scepticism about the 
concept of thyroid cancer overdiagnosis and overtreat-
ment, and overdiagnosis and overtreatment information 
generally. This information was new to all participants, 
and seemed to cause some initial uncertainty and raise 
additional thoughts and questions. However, as each of 
the sessions progressed, there was a shift to more of a 
general acceptance and understanding of the informa-
tion. Participant’s questions and responses shifted and 
indicated to researchers that they were able to thought-
fully engage with the information presented. Alongside 
the acceptance and understanding of overdiagnosis and 
overtreatment came a sense of concern from participants 
that they had not been informed or educated about 
this type of information before. Participants expressed 
concern that this information was not public knowl-
edge and queried whether this information was being 
discussed with current patients, as they felt it should be. 
Overall, there was a strong desire for more information 
Table 1 Participant characteristics (n=47)
Characteristic Frequency n (%)
Age
  18–34 18 (38.3)
  35–49 11 (23.4)
  50–64 9 (19.1)
  65+ 9 (19.1)
Sex
  Male 21 (44.7)
  Female 26 (55.3)
Education
  University degree 19 (40.4)
  Diploma, certificate or 
apprenticeship
19 (40.4)
  Higher school certificate or leaving 
certificate
8 (17.0)
  No school or other qualifications 1 (2.1)
Marital Status
  Married/living with partner 30 (63.8)
  Divorced/separated 4 (8.5)
  Widowed 2 (4.3)
  Single 11 (23.4)
Employment
  Full time 22 (46.8)
  Part time 11 (23.4)
  Retired 9 (19.1)
  Studying 1 (2.1)
  Other 4 (8.5)
Main language spoken at home
  English 42 (89.3)
  Other 5 (10.7)
Aboriginal/Torres Strait Islander
  No 46 (97.9)
  Aboriginal 1 (2.1)
  Torres Strait Islander 0 (0)
  Aboriginal and Torres Strait Islander 0 (0)
Health literacy*
  Adequate health literacy 44 (93.6)
  Limited/marginal health literacy 3 (6.4)
Personal cancer diagnosis†
  No 44 (93.6)
  Yes 3 (6.4)
Immediate family member diagnosed 
with cancer
  No 18 (38.3)
  Yes 29 (61.7)
Cancer worry‡
  Not worried at all 14 (29.8)
Continued
Characteristic Frequency n (%)
  A bit worried 25 (53.2)
  Quite worried or very worried 7 (14.9)
General anxiety (mean score)§ 28.7
*Single Item Literacy Screener.27
†Other than thyroid cancer.
‡A validated single item that measures level of worry about 
developing cancer, using four response categories ranging from 
not worried at all to very worried.28 One response missing. 
§State trait anxiety inventory (short form), on a scale from 20 to 80, 
with higher scores indicating greater levels of anxiety.29 30
Table 1 Continued 
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and greater public and patient education about these 
topics in relation to low-risk thyroid cancer, as well as 
other low-risk cancers.
That doesn’t make sense to me. What about those 
cancers that have been widely researched and tested. 
(FG1)
I wasn’t aware of this, like, overdiagnosis and over-
treatment. All I’m told is, you have to get checked 
and you have to do this. (FG3)
Understanding and support for reducing overdiagnosis and 
overtreatment
There were many participants who voiced their under-
standing and support for reducing overdiagnosis and 
overtreatment. Some felt that it was probably better not 
knowing that a low-risk cancer was present in the first 
place. If diagnosed themselves many expressed that they 
saw active surveillance as a good way to potentially reduce 
overtreatment. Some participants also felt it important that 
reducing overdiagnosis, and in particular overtreatment, 
would reduce financial costs for both patients and the 
healthcare system.
It just sounds like it’s better not knowing. (FG5)
It’s a cancer that you don’t, you wouldn’t even know 
that it was there. It’s not affecting your life… if I per-
sonally got diagnosed and if it wasn’t like a big med-
ical thing and I didn’t need the, um, surgery, then I 
probably wouldn’t. (FG4)
Overdiagnosis and then overtreatment we’re really 
creating a, a higher cost to the medical system for 
something that’s just staying sort of baseline for most 
individuals. (FG6)
Concern about the implications of overdiagnosis and overtreatment
A number of participants voiced concerns about the 
implications of thyroid cancer overdiagnosis and over-
treatment. Their main concern was regarding the uncer-
tainty of the risk of overdiagnosis and overtreatment. 
These participants were uncomfortable with the idea that 
at this time it is not known at an individual level who may 
be overdiagnosed and overtreated. Some participants 
were also concerned about the impact that this informa-
tion may have on patient’s quality of life. They felt that 
giving this information to someone and recommending 
active surveillance instead of treatment would be psycho-
logically hard to deal with.
So you really don’t know, or no one knows if overtreat-
ment is actually happening? So like you’re surmising 
that it is happening but no one knows yet. (FG2)
I guess it could be like a scary thing to live with also, 
just thinking, oh well something might have changed, 
um, maybe I do need to get surgery? Just constantly 
kind of thinking, oh what if. (FG4)
Views and opinions about the strategy of changing the 
terminology
The majority of participants were open to the idea of 
changing the terminology of low-risk thyroid cancers. 
However, some participants were quite unsure about 
how they felt about the idea, and a small group of partic-
ipants remained strongly opposed throughout the discus-
sions. Overall, participants understood and accepted the 
concept of the proposed strategy, although a few partic-
ipants still struggled with how the strategy would ulti-
mately work and what it would mean for them (as patients 
or community members).
I’m fine with it being changed. I think I’m actually 
for it … but I do think you do need to be informed. 
(FG6)
…it’s such a big shift in thinking and maybe, maybe 
that’s what’s making me feel uncomfortable. (FG1)
Reasons for supporting changing the terminology
The most dominant reason for participants supporting 
changes to cancer terminology was the psychological 
impact and stigma associated with the term ‘cancer’. 
Overall, participants believed that the word ‘cancer’ 
was frightening and anxiety provoking, and suggested 
it may drive the preference for immediate treatment. 
Other ideas discussed included that the current defini-
tion of cancer may not actually represent the nature of 
this condition (as this type of thyroid cancer was lower 
risk than what they understood cancer to be), and that 
changing the terminology would help with the potential 
insurance difficulties current cancer patients may face.
As soon as you get that word ‘cancer’ it triggers, um, 
a reaction which is always negative. And it’s like this 
perception that it’s got to be treated. (FG3)
It’s our association with the word cancer. So I think 
cancer, doom and gloom… But if there’s such a low- 
risk of someone dying from it, why phrase it and coin 
it cancer at all? (FG1)
Reasons against changing the terminology
The main reason participants expressed for being unsure 
about or strongly opposed to changing the terminology 
was the worry about the risk of progression. These partic-
ipants did not feel comfortable with removing the term 
‘cancer’ from diagnoses if there was a small risk that 
the tumour could progress and become more harmful. 
Participants also felt that changing the terminology would 
mask the truth of the diagnosis as it was technically still a 
cancer, and could cause confusion, particularly if patients 
searched the internet and discovered that their condi-
tion used to be referred to as cancer. Some participants 
were additionally worried that patients may not adhere 
to appropriate follow-up or management measures if the 
condition was not called cancer.
…what if I am part of that 3.8%, where it has actually 
spread? That would not sit well with me. (FG3)
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Whether it be low-risk or high risk, it’s still cancer. 
(FG6)
I think maybe changing those things might make me 
very gung ho and think, oh right, you know, I might 
not go for my next test. (FG2)
Views and opinions about alternative terminology
Participants had greatly varying opinions about termi-
nology for low-risk thyroid cancers, and could not reach 
agreement on an alternate term. Some participants 
preferred the term ‘abnormal cells’, being familiar with 
this term’s use for low-risk cervical lesions, while others 
disagreed, stating that ‘abnormal’ was equally anxiety 
provoking. Participants also voiced opinions on various 
possible terms to describe low-risk thyroid cancer (eg, 
preinvasive cancer, lump, lesion, nodule). A few partic-
ipants suggested that rather than changing the termi-
nology, some sort of risk stratification terminology could 
be used to describe the condition. Mainly participants 
wanted terminology that was clear, understandable (ie, 
did not include a lot of medical jargon) and would not 
cause confusion or further anxiety.
…it is abnormal but it’s not introducing that, that 
fear factor word attached to it. (FG1)
Abnormal you can get some people anxious, ‘cause 
it’s like not normal… What’s not normal about it? 
(FG3)
So I think you, you call it something like low risk 
cancer or something like that… Or something that 
still calls it a cancer but actually gives it an appro-
priate risk factor. (FG1)
Other proposed strategies
Aside from changes to terminology, participants felt 
strongly about two proposed strategies to reduce poten-
tial overdiagnosis and overtreatment of low-risk thyroid 
cancer. The first was the importance of medical profes-
sional involvement in informing and discussing these 
issues with patients (if they were not already doing so). 
The majority of participants felt that there was a need 
for clear explanations around the diagnosis of thyroid 
cancer (and cancer generally) and treatment options. 
The second strategy that was suggested was the need for 
better public education. Participants were unsure of why 
they had not heard about information on overdiagnosis 
and overtreatment of low-risk thyroid cancer or low-risk 
cancer generally before and suggested campaigns to 
promote greater public awareness.
It’s very important for the doctor/patient relation-
ship that if you are diagnosed with, with this, you 
know, as a result of something else, that information 
that, like you’ve shown us today, you’ve spoken to us 
today, is made very clear to the, to the patient. (FG3)
To me it’s more about the education of what it means, 
rather than changing the name because it’s scary. 
(FG2)
Maybe if the public was sort of educated in the same 
way you’ve just, you know, explained things to us… 
people would, um, make a more informed opinion 
about what they want to do. (FG3)
DIsCussIOn
This study sheds light on public perceptions of informa-
tion on thyroid cancer overdiagnosis and overtreatment, 
and potential strategies to help mitigate these in low-risk 
thyroid cancer and other similar conditions. Consistent 
with earlier studies, this community sample had a low 
pre-existing general awareness of overdiagnosis and 
overtreatment,32–37 including issues specifically related 
to thyroid cancer. The latter is not surprising as there is 
no formal screening programme in Australia, and testing 
does not receive the publicity that cancers like breast, 
prostate and lung cancer receive. There was initially scep-
ticism among participants about the concept of overdiag-
nosis and overtreatment; however, as more information 
was provided, participants appeared to understand and 
accept the concepts and accept active surveillance as a 
possible alternative management strategy to mitigate 
overtreatment in low-risk thyroid cancer. These findings 
mirror other community-based studies that also indi-
cate preferences towards active surveillance.16 17 38 We 
observed, however, wide variation in views with some 
residual concerns about the evidence for overdiagnosis, 
and in particular, overtreatment of thyroid cancer.
Similar to the medical community,10 there is variation 
in the public’s views about whether changing the termi-
nology of low-risk thyroid cancer (and other low-risk 
cancers) is an adequate strategy to help reduce overdi-
agnosis and overtreatment. Our study participants were 
also uncertain about an appropriate and acceptable alter-
native term to replace ‘cancer’. Reservations concerned 
worry about the risk of further progression of the disease 
and the need to still take the condition seriously, even if 
the terminology were changed. Concern about the risk 
of progression to invasive disease and the evidence of 
overdiagnosis and overtreatment is not surprising as it 
has been shown to be a factor driving clinician manage-
ment recommendations.10 Furthermore, not being able 
to individually select who may be impacted was difficult 
for participants to comprehend and accept which has 
been voiced as a concern in understanding and commu-
nicating overdiagnosis information previously.32 33 35
Notably, there was a strong overarching desire for greater 
patient and public education around overdiagnosis and 
overtreatment in cancer to complement any revisions to 
terminology. Participants wanted greater medical profes-
sional involvement in informing patients about relevant 
evidence and an increase in public health campaigns 
with information on these topics. Other studies have 
found that information on overdiagnosis and overtreat-
ment is strongly desired by patients.37 In addition, studies 
demonstrate that those who should be the main source 
of providing such information to patients are physicians, 
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and often physicians themselves do not have adequate 
understanding or knowledge on the extent or harms of 
overdiagnosis.39 40 Although widespread implementa-
tion of this information may take time, strategies beyond 
changing disease terminology including mass media 
education, shared decision-making through patient deci-
sion aids and citizen juries have all also been suggested to 
be potentially effective for communicating about overdi-
agnosis or overtreatment.41 Box 2 summarises issues to 
consider when communicating to patients and the public 
about low-risk conditions.
Our study had both strengths and limitations. To our 
knowledge, this is the first study to investigate community 
perceptions of information about thyroid cancer overdi-
agnosis and overtreatment and community responses to 
the possibility of changing the name of low-risk PTCs. 
We had an adequate sample size for qualitative research 
which included participants of different age, gender and 
socioeconomic status. Participants were recruited via 
random digit dialling by an independent professional 
recruitment company.
The main limitation of our study was the amount and 
complexity of information that was presented to partici-
pants during the 2-hour focus group. Since participants 
were hearing this information for the first time in this 
short time period, participants may not have comprehen-
sively understood each concept. We did not test partici-
pants’ understanding; although our data indicated that 
most people engaged thoughtfully with the question of 
a terminology change and understood the information. 
Moreover, the qualitative nature of our study did not 
allow us to quantify the prevalence of public perceptions 
or preferences towards a change in terminology, rather it 
was used to explore a range of views and opinions which 
may lack generalisability. These views may have been 
influenced by the investigator’s interactions during the 
presentation or by the views expressed by other partici-
pants. Furthermore, it can be argued that the thematic 
analysis may be prone to bias due to the dependence of 
the raters. However, this qualitative approach offers the 
advantage of potentially identifying themes or issues that 
may not have been apparent a priori. Additionally, to help 
ensure any bias related to presentation was minimised we 
arranged for it to be reviewed by two independent thyroid 
cancer clinicians (an international endocrinologist and a 
national thyroid surgeon). It was also piloted three times 
in order to ensure comprehensibility.
In conclusion, many community members in our study 
were open to a change in the terminology to describe 
low-risk cancer, but there were considerable variability 
in the public’s willingness to accept this proposal. Partic-
ipants, even those supportive of a change in terminology, 
were unable to propose an appropriate alternative termi-
nology. Consequently, we conclude that some citizens 
might not accept a change in nomenclature to low-risk 
cancers, and could feel very unsure of or even resistant 
to changes in terminology. If such a change were to go 
ahead, careful consideration of how to inform both the 
public and current patients about the implications of the 
change, including changes to current patients’ follow-up 
or treatments, would be needed. Involving community 
members and consumers in the renaming process could 
help ensure that any change to terminology will be under-
stood and accepted by the public and patients alike. More-
over, there is a strong and apparently widely held desire 
for more information—to patients and to the public—
on the topic of cancer overdiagnosis and overtreatment. 
Enhanced information provision would be essential to 
complement a change in terminology for PTC and other 
low-risk cancers.
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